Session 3: Update in Psychopharmacology and General Hospital Psychiatry

Egg Harbor, WI US
July 22, 2024 to July 23, 2024
Delirium is a syndrome of neuropsychiatric signs and symptoms that can accompany severe medical conditions. It is an independent risk factor for increased morbidity and mortality and is associated with increased lengths of stay and costs of care. Despite this, it frequently goes unrecognized, and debate continues about the best prevention and treatment strategies. We will review the current best practices for identifying, preventing, and treating delirium to improve outcomes and minimize adverse events. Substance Use Disorders (SUDs) represent a public health crisis. Medical admissions for this at-risk patient population are increasing. Unfortunately, administrative hurdles, legal challenges, and associated stigma complicate the assessment and treatment of SUDs in the inpatient medical setting. We will outline various identification and management options for alcohol and opioid use disorders commonly encountered in the hospital setting. Challenging patient interactions are present in all types of healthcare settings. Addressing the patient's needs, managing staff distress, and identifying our feelings are essential to safe management and resolving these demanding situations. Adverse effects of psychiatric medications vary from those that may be a nuisance to more severe and potentially life-threatening adverse events. We will review the diagnosis, pathophysiology, and treatment of neuroleptic malignant syndrome and serotonin syndrome. Awareness of these possible adverse effects is essential because they are associated with physical morbidity and mortality.

Last year, a paper stating that there is no evidence regarding serotonin deficiency in major depression brought about a new controversy in the field of psychopharmacology.  We will reexamine the monoamine theory of depression and newer concepts in the neurobiology of major depression.  We will look at the antidepressants available now. There have been six medications approved by the FDA in the last 15 years for treatment of major depression.  These include three new mechanisms—NMDA receptor antagonism, GABA—A receptor modulators, and 5HT-1 receptor agonism.  We will look at these mechanisms and the data behind them.

Thorazine was the first widely used anti-psychotic and its structure gave rise to almost half of the psychoactive agents we now have available. In the last 15 years, four new antipsychotics have been approved by the FDA. We will discuss these in detail. Exciting potential antipsychotics are being tested based on the muscarinic system and the Trace amine-associated receptor 1 (TAAR1).  We will critique where these mechanisms may be beneficial. Finally, we will scrutinize Alzheimer’s disease and the new anti-amyloid treatments and the FDA’s approval of brexpiprazole for agitation in Alzheimer’s disease means for clinical practice.

Target Audience

  • ​​​​​Physicians
  • Nurse Practitioners
  • Physician Assistants
  • Nurses
  • Pharmacists
  • Psychologists
  • Social Workers
  • Psychiatry Residents
  • Medical Students
  • Allied Health Professionals

Learning Objectives

Participants who engage in this education intervention will be able to:

  • Identify the mechanisms of action of newer antidepressants
  • Identify the mechanisms of new and potential antipsychotics
  • Describe anti-amyloid therapies and their place in geropsychiatry
  • Describe various management techniques to address challenging patient interactions in a healthcare setting
Additional information

Contact

Name: 
Caimen Masterson
Phone Number: 
+1 (414) 955-7250
Course summary
Available credit: 
  • 8.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 8.00 APA
    APA credit.
  • 8.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
03/18/2024
Course expires: 
11/30/2024
Event starts: 
07/22/2024 - 8:30am CDT
Event ends: 
07/23/2024 - 12:35pm CDT
Cost:
$387.00

Monday:

  • Review of Antidepressants and Major Depression
    • Serotonin controversy
    • Serotonin deficiency to the neurobiology of major depression
    • Antidepressants—the beginning
    • Some newer antidepressants in detail
    • New mechanisms and very new agents
  • Delirium: Identification, management, and prevention
  • Serotonin syndrome and neuroleptic malignant disorder

Tuesday:

  • Review of Antipsychotics and the dopamine hypothesis
    • Thorazine and where has it taken us
    • Some newer antipsychotics in detail
    • New potential antipsychotics and new mechanisms
  • Update in Geropsychiatry
    • Alzheimer’s disease review
    • Treatments for Alzheimer’s today
  • Substance use disorders in the general medical hospital
  • Managing challenging patient interactions in a medical setting
The Landmark Resort
4929 Landmark Drive
Egg Harbor, WI 54209
United States
+1 (800) 273-7877

Lodging in July and August is in great demand; you must make reservations early. A block of suites has been set aside at the Landmark Resort. These suites will be held until June 7th, 2024, or until they are filled. After that, the rooms are on a space-available basis.

From its site on the bluff, the Landmark offers outstanding views of the waters of Green Bay with 294 units comprised of 1, 2, and 3-bedroom suites. Facilities include the Carrington Pub and Grill, 10 meeting and function rooms, 1 indoor and 3 outdoor pools, 2 tennis courts, whirlpools and steam rooms, and a fitness center and game room. The Landmark Resort is Door County’s largest and best full-service facility. As of May 2017, all suites at the Landmark have been renovated! Visit their website for photos and details.

The Landmark Resort
4929 Landmark Drive
Egg Harbor, Wisconsin 54209
Reservations: (800) 273-7877
http://www.thelandmarkresort.com

To book through our discounted group rate, please call the Landmark reservation line at (800) 273-7877 and state that you are attending the Door County Summer Institute. No group code is required. Group rates cannot be booked online.

Thomas Heinrich, MD, Professor of Psychiatry and Family Medicine at the Medical College of Wisconsin (MCW), completed a combined residency in psychiatry and family medicine, followed by a fellowship in consultation psychiatry at Massachusetts General Hospital. He is board-certified in family medicine and general adult psychiatry and holds subspecialty certification in consultation-liaison psychiatry and neuropsychiatry. Clinically, Dr. Heinrich remains active in consultation psychiatry, working on a busy academic psychiatric consultation service at Froedtert Hospital. This quaternary care academic medical center serves as MCW’s primary teaching hospital. Administratively, Dr. Heinrich currently serves as Director of the Division of Consultation-Liaison Psychiatry and Executive Vice-Chair in the Department of Psychiatry and Behavioral Medicine at MCW. In addition, he is the Medical Director of Behavioral Health at Froedtert Hospital and the Physician Lead for implementing Froedtert and the Medical College of Wisconsin’s multidisciplinary behavioral health strategic plan. He has collaborated with multiple stakeholders in these roles to develop and implement several innovative cross-disciplinary and inter-institutional clinical programs.

Harold H. Harsch, MD, is a Professor of Psychiatry and Behavioral Medicine at the Medical College of Wisconsin (MCW).  Dr. Harsch attended medical school at the Medical College of Wisconsin, completed an internship in internal medicine at the University of Texas at Galveston, and completed his psychiatric training and behavioral medicine fellowship at Stanford University Medical Center in California. He has been board certified in adult psychiatry, geriatric psychiatry, and psychosomatic medicine.  

Dr. Harsch has been involved in over 100 clinical trials of new drug development. He has been a consultant to most major pharmaceutical companies. He has been involved with brain stimulation procedures for treatment resistant depression. He currently teaches Advanced Psychopharmacology to psychiatric residents at the Medical College of Wisconsin. Currently he supervises residents and fellows at the Froedtert/MCW Geropsychiatry clinic, the MCW resident psychiatry clinic, and the Froedtert Consultation-Liaison Program.


Activity Director:
Carlyle H Chan, MD
Professor of Psychiatry and 
the Institute for Health and Equity-Bioethics and Humanities
Medical College of Wisconsin

Planning Committee Members:
Robert Huberty, MSW, LCSW
Program Director
Department of Psychiatry and Behavioral Medicine
Medical College of Wisconsin

Ellen Leitner, LCSW
Department of Psychiatry and Behavioral Medicine
Medical College of Wisconsin

Kevin Bozymski, PharmD, BCPS, BCPP
Assistant Professor, Department of Clinical Science
Medical College of Wisconsin School of Pharmacy 
Assistant Professor, Department of Psychiatry and Behavioral Medicine
Medical College of Wisconsin

Kylie Lenz, PA-C
Physician Assistant 
Department of Psychiatry and Behavioral Medicine
Medical College of Wisconsin

Heather M. Smith, PhD, ABPP
Lead Psychologist
Director of Psychology Training
Milwaukee VA Medical Center
Associate Professor
Department of Psychiatry and Behavioral Medicine
Medical College of Wisconsin

Jessica Reyes-Roberson, APNP
Department of Psychiatry and Behavioral Medicine
Medical College of Wisconsin

In accordance with the ACCME® Standards for Integrity and Independence in Accredited Continuing Education, Standard 3, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.

  • Carlyle H Chan

  • Robert Huberty

  • Ellen Leitner

  • Kevin Bozymski

  • Kylie Lenz

  • Heather M. Smith

  • Jessica Reyes-Roberson

  • Thomas Heinrich

  • Harold Harsch

Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 8.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Professionals:
The Medical College of Wisconsin designates this live activity for up to 8.00 hours of participation for continuing education for allied health professionals.

National Association of Social Workers Credit Statement:

This program is pending approval by the National Association of Social Workers (Approval # XXXXXXXXXX) for 8 continuing education contact hours.

Psychology CE Credit Statement:
The Medical College of Wisconsin is approved by the American Psychological Association to sponsor continuing education for psychologists.  The Medical College of Wisconsin maintains responsibility for this program and its content.

This activity contains content or processes that may be potentially stressful.

MCW's Psychology Continuing Education Grievance Policy

Available Credit

  • 8.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 8.00 APA
    APA credit.
  • 8.00 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$387.00
Please login or register to take this course.

Early Bird pricing will be available through June 15th, 2024. After that, prices will increase as noted below.

FeeAttendee TypeAmount
Two-Day In Person Registration (Early Bird)Physicians, psychologists, pharmacists, physician assistants, APPs and other Health Professionals$360.00
Two-Day In Person RegistrationPhysicians, psychologists, pharmacists, physician assistants, APPs and other Health Professionals$385.00
Two-Day In Person Registration (Early Bird)Medical students, grad students, residents$295.00
Two-Day In Person RegistrationMedical students, grad students, residents$335.00

All registrations will be assessed $27.00 non-refundable processing fee.

PLEASE NOTE! The billing address entered upon checkout must match the billing address on the credit card you will be using to pay for this course. MCW accepts MasterCard, VISA and Discover card.

For a more user-friendly registration and payment experience, Google Chrome and Mozilla Firefox are the recommended web browsers.


Registration scams:

Registration for courses managed by MCW Office of Continuing Professional Development can only be completed through our portal at https://ocpe.mcw.edu/. Course registrations made through other sites cannot be honored. MCW Office of Continuing Professional Development is not able to refund fees paid through unaffiliated registration sites, such as eMedEvents.com, MedConfWorld.com, EventEgg.com, and 10times.com.

Please report any unauthorized websites or solicitations for registrations to cme@mcw.edu